Sapient Launches Tumor Protein Mapping Platform for Oncology

SAN DIEGO, Calif., April 28, 2026

Sapient has announced the launch of its Tumor Protein Mapping Platform, a next-generation suite of mass spectrometry-based discovery proteomics workflows designed to characterize functional tumor biology across four critical dimensions: the druggable tumor cell surface proteome, phosphorylation-driven signaling pathways, tumor immune microenvironment, and therapeutic resistance mechanisms. The platform introduces four specialized workflows — SurfaceSeek™, SignalingSeek™, ImmuneSeek™, and ResistanceSeek™ — enabling biopharma sponsors to gain deeper and more precise insights into tumor biology using both fresh-frozen and FFPE human tumor samples.

Advancing Precision Oncology Through Multi-Dimensional Proteomics

At the core of the platform is SurfaceSeek™, a specialized workflow developed to identify and validate druggable tumor cell surface proteins for advanced therapeutic modalities such as antibody-drug conjugates (ADCs), T-cell engagers, and radioligand therapies. By combining Sapient’s advanced discovery proteomics with selective enrichment of mature N-linked glycoproteins, SurfaceSeek directly measures proteins that are functionally expressed on the extracellular tumor surface.

This provides critical insights into target accessibility, density, tumor selectivity, and extracellular therapeutic compatibility, while also enabling peptide-level resolution of protein isoforms and post-translational modifications. This direct measurement approach reduces dependency on genomic inference and strengthens confidence in target selection for oncology drug development.

Comprehensive Functional Biology Mapping for Better Drug Development

Beyond surface protein discovery, the platform includes SignalingSeek™, ImmuneSeek™, and ResistanceSeek™, each designed to uncover key biological mechanisms influencing therapeutic outcomes. SignalingSeek™ quantifies phosphorylation events across major oncogenic pathways, allowing researchers to assess pathway activation, on-target drug effects, and adaptive resistance mechanisms.

ImmuneSeek™ evaluates active immune cell populations and immune pathway signaling that drive therapeutic response or suppression within the tumor microenvironment. Meanwhile, ResistanceSeek™ maps coordinated protein networks that tumors use to adapt under therapeutic pressure, helping developers anticipate resistance across multiple treatment modalities.

These integrated workflows provide a multi-dimensional protein-level understanding of cancer biology, enabling oncology teams to make high-stakes drug development decisions with direct biological evidence rather than indirect assumptions. Importantly, Sapient’s platform demonstrates strong concordance in both fresh-frozen and FFPE samples, unlocking the ability to retrospectively analyze vast archived tissue repositories previously underutilized for functional proteomics.

Supporting Faster and Smarter Biopharma Decision-Making

Sapient’s leadership emphasized that the platform was built in response to growing industry demand for more reliable methods to evaluate therapeutic targets and response mechanisms. By offering all four workflows as standalone services or combined integrated solutions, the company allows biopharma sponsors to tailor tumor characterization strategies based on program needs. This capability is further strengthened by Sapient’s DynamiQ™ Tumor-Tissue virtual biobank, which provides streamlined access to annotated FFPE tumor samples for accelerated translational research.

With oncology drug development increasingly dependent on precise biomarker discovery and target validation, Sapient’s Tumor Protein Mapping Platform represents a major advancement in precision medicine and translational oncology research. By moving beyond genomic analysis and delivering direct measurement of functional tumor biology, Sapient is helping reshape how next-generation cancer therapies are discovered, validated, and advanced toward clinical success.

Source: Sapient press release